Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Carrie G Lenneman, MD, MSCI
Vanderbilt-Ingram Cancer Center & Univ. of Louisville
Principal Investigator - Daniel Lenihan, MD
Vanderbilt University
Principal Investigator - Douglas B Sawyer, MD, PhD
Vanderbilt University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky, United States
- Mbccop - Meharry Medical College - Nashville
Nashville, Tennessee, United States
- Vanderbilt Heart One Hundred Oaks
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2008
- Primary completion
- 31 Mar 2015
- Completion
- 31 Mar 2015
- Last update posted
- 19 Feb 2018
- Registered enrollment
- 133
- Registry id
- NCT00875238
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.